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Abstract
Background/Objective: Visfatin, also known as nicotiamide phosphoribosyltransferase or pre-B cell colony enhancing
factor, is a pro-inflammatory cytokine whose serum level is increased in sepsis and cancer as well as in obesity. Here we
report a pro-inflammatory role of visfatin in the brain, to mediate sickness responses including anorexia, hyperthermia and
hypoactivity.
Methodology: Rats were intracerebroventricularly (ICV) injected with visfatin, and changes in food intake, body weight, body
temperature and locomotor activity were monitored. Real-time PCR was applied to determine the expressions of pro-
inflammatory cytokines, proopiomelanocortin (POMC) and prostaglandin-synthesizing enzymes in their brain. To determine
the roles of cyclooxygenase (COX) and melanocortin in the visfatin action, rats were ICV-injected with visfatin with or without
SHU9119, a melanocortin receptor antagonist, or indomethacin, a COX inhibitor, and their sickness behaviors were evaluated.
Principal Findings: Administration of visfatin decreased food intake, body weight and locomotor activity and increased
body temperature. Visfatin evoked significant increases in the levels of pro-inflammatory cytokines, prostaglandin-
synthesizing enzymes and POMC, an anorexigenic neuropeptide. Indomethacin attenuated the effects of visfatin on
hyperthermia and hypoactivity, but not anorexia. Further, SHU9119 blocked visfatin-induced anorexia but did not affect
hyperthermia or hypoactivity.
Conclusions: Visfatin induced sickness responses via regulation of COX and the melanocortin pathway in the brain.
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Introduction
Sickness responses such as anorexia and changes in energy
metabolism are closely related to inflammatory diseases [1,2].
Inflammation-associated anorexia refers to reduced food intake
during acute and chronic inflammatory states in both human and
animals. It is well known that laboratory animals reduce their food
intake in response to administration of pro-inflammatory cytokines
or agents that stimulate cytokine release such as lipopolysaccharide
(LPS) [3,4,5].
Inflammation affects the central nervous system and results in
the manifestation of sickness symptoms [6]. Inflammation in the
brain elicits a state of profound negative energy balance that is an
adaptive response to infection [1] and induces sickness responses
such as fever, anorexia, weakness and hypoactivity [2]. A number
of inflammatory stimuli activate hypothalamic pro-inflammatory
cytokines, including tumor necrosis factor-a (TNF- a), interleukin
1-b (IL1-b) and IL-6, which is involved in anorexia and febrile
responses. Conversely, inhibition of cytokine production or action
attenuates these inflammation-induced sickness responses [7,8].
Recent studies have suggested that synthesis and release of pro-
inflammatory cytokines in response to pathophysiological process-
es induce anorexia and increase metabolic rate by acting upon the
brain region responsible for energy homeostasis [9,10].
Visfatin has been recently identified as a peptide predominantly
expressed in and secreted from visceral fat in both humans and
mice [11,12]. This protein is also known as an enzyme for the
biosynthesis of NAD
+, which influences a variety of metabolic and
stress responses [13]. Although recent studies have emphasized its
role as an adipose hormone that mediates pro-inflammatory
actions in various metabolic diseases like obesity, type 2 diabetes
and cardiovascular disease [13], visfatin was originally identified as
a pre-B cell colony enhancing factor (PBEF) and is thought to play
roles in immune response and inflammation [14,15,16,17]. Thus,
there is some evidence to suggest that visfatin activates pro-
inflammatory cytokines in human monocytes [18]. Additionally,
serum visfatin concentration is increased in patients with sepsis,
chronic kidney disease and cancer [19,20,21], which indicates that
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e15981visfatin plays a pro-inflammatory role in peripheral tissues.
However, little is known about its function in the brain.
Accordingly, the aim of the present study is to identify the roles
of visfatin in energy metabolism and in sickness responses in the
brain. We assessed changes in food intake, body temperature and
locomotor activity after intracerebroventricular (ICV) administra-
tion of visfatin and identified the molecular mechanisms of these
physiological responses.
Results
Effects of visfatin on food intake and body weight
In order to assess the central role of visfatin in energy
homeostasis, rats were injected with recombinant rat visfatin into
the lateral ventricle. Administration of visfatin significantly
decreased cumulative food intake measured at 4-h intervals for
24 h after injection of visfatin (Fig. 1A). Significant differences
were observed between the visfatin- and vehicle-injected groups
beginning 8 h after visfatin injection. To confirm the effect of
visfatin on feeding behavior, visfatin was ICV-injected into
animals that had fasted for 24 h, in whom a strong appetite was
induced. Visfatin significantly decreased food intake 4 and 24 h
after re-feeding in food-deprived animals (Fig. 1B). To determine if
the anorectic effect of visfatin affects body weight, rats was
weighed immediately prior to visfatin injection and 24 h after the
injection. Control animals showed an average of 4.4 g of weight
gain during the first day, while visfatin-injected rats lost an average
of 7.3 g (Fig. 1C). Interestingly, weight loss in visfatin-injected rats
was significantly greater than that of the pair-fed group that was
given the same amount of food. This suggests that central
administration of visfatin may have affected energy expenditure as
well as food intake.
Visfatin-induced hyperthermia and hypoactivity
We evaluated body temperature and locomotor activity in rats
injected with visfatin. As shown in Fig. 2A, locomotor activity in
visfatin-treated rats during the dark period was significantly lower
than that of vehicle-treated rats. Vehicle-treated control rats
showed circadian changes in body temperature: low during the
light period and high during the dark period. Rats administered
visfatin 2 h before the dark period showed an increase in body
temperature beginning 2 h after injection and peaking 8 h after
injection (Fig. 2B). This increase in body temperature continued
until the start of the light period.
Visfatin stimulates hypothalamic factors involved in
inflammatory responses
To determine whether visfatin is involved in hypothalamic
inflammation, we assessed its effect on the expressions of pro-
inflammatory cytokines and prostaglandin-synthesizing enzymes
in the rat hypothalamus. ICV administration of visfatin increased
the expressions of TNF-a and IL1-b in the hypothalamus (Figs. 3A
and B). Moreover, there were significant increases in cyclooxy-
genase 2 (COX2), a rate-limiting enzyme that converts arachi-
donic acid into prostaglandins, and microsomal prostaglandin E
synthase-1 (mPGES1), a specific catalyzing enzyme for the final
step of prostaglandin E2 (PGE2) biosysthesis (Figs. 3C and D).
These results suggest that visfatin may be involved in an
inflammatory response in the brain by activating the syntheses
of inflammatory mediators.
COX inhibitor blocks visfatin-induced hyperthermia and
hypoactivity, but not anorexia
Because we found that visfatin stimulated the expressions of
COX2 and mPGES1 genes in the hypothalamus, we hypothesized
that visfatin might exert its effect on sickness behaviors by
regulating the syntheses of prostaglandins. To investigate this
possibility, rats were intraperitoneally (IP) injected with indometh-
acin, a COX inhibitor, 30 min prior to the injection of visfatin,
and their sickness responses were observed. Indomethacin
completely abolished visfatin-induced hyperthermia during the
observation period (Fig. 4A), and visfatin-induced hypoactivity
(Fig. 4B) and weight loss (Fig. 4C) were partially blocked by the
same treatment. However, indomethacin did not affect visfatin-
induced decrease of food intake (Fig. 4D). These results suggest
that visfatin affects body temperature and locomotor activity via
prostaglandin activities. Additionally, its effect on food intake may
be mediated by a different pathway.
Effect of visfatin on a-melanocyte stimulating hormone
(a –MSH) synthesis
To investigate whether visfatin exerts an anorexic effect by
regulating the hypothalamic melanocortin pathway that is well-
Figure 1. Effects of ICV administration of visfatin on food intake and body weight. Food intake and body weight were measured in rats
that had received an ICV injection of visfatin. (A) Cumulative food intake was measured for one day at 4 h intervals after an ICV injection of visfatin.
Control animals received a 0.9% saline solution. (B) Effect of visfatin on food intake in rats showing strong appetites induced by food deprivation for
one day. (C) Effect of visfatin on body weight changes one day after ICV injection. Data are represented as mean 6 SEM (n=10). *P,0.05, **P,0.01
and ***P,0.001 vs. control rats;
###P,0.001 vs. visfatin-injected rats.
doi:10.1371/journal.pone.0015981.g001
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MSH and proopiomelanocortin (POMC) were determined in rats
injected with visfatin using immunohistochemistry (IHC) and real-
time PCR, respectively. Food deprivation for one day significantly
decreased a-MSH protein (Fig. 5A) and POMC mRNA (Fig. 5B)
levels in the hypothalamic arcuate nucleus (ARC), in agreement
with prior findings [22]. Interestingly, visfatin completely reversed
the effect of fasting and the subsequent decreases in a-MSH
protein and POMC mRNA levels. In fact, visfatin increased the
expressions of both peptides compared to those of untreated
control rats (Figs. 5A and B). However, indomethacin did not
affect vsifatin-induced enhanced POMC expression (Fig. 5C).
These results suggest that the anorexic effects of visfatin may be
caused by its effect on the syntheses of POMC and a-MSH and
not via prostaglandins.
Effect of a melanocortin receptor antagonist on visfatin-
induced anorexia
It has been well established that a-MSH decreases food intake
by acting through melanocortin receptors 3 and 4 (MC3/4R) [23].
Accordingly, we examined whether the anorectic effect of visfatin
is mediated by MC3/4R using rats ICV-injected with SHU9119,
an MC3/4R antagonist. When SHU9119 was pre-administered to
rats 30 min prior to the visfatin injection, it completely blocked the
anorectic effect of visfatin (Fig. 6A), indicating that visfatin-
induced anorexia is mediated by MC3/4R. Next, we examined
the effects of SHU9119 on visfatin-induced hypoactivity and
hyperthermia in the same group of rats. ICV administration of
SHU9119 did not change the effect of visfatin on locomotor
activity (Fig. 6B) or body temperature during the 24-h observation
period (Fig. 6C). However, it further increased body temperature
from the visfatin-increased level during the initial 8 h following
injection of SHU9119 (Fig. 6C). The areas under the curves of the
two groups (visfatin and visfatin + SHU9119) significantly differed
during this period (P,0.001).
Discussion
Since the discovery of visfatin expression in visceral fat, several
studies have reported correlations between serum visfatin
concentration and expression with obesity, but the relationship
Figure 2. Effects of visfatin on locomotor activity and body temperature. Locomotor activity and body temperature were measured for
24 h after ICV administration of visfatin. (A) ICV injection of visfatin resulted in decreased locomotor activity during the dark period, but there wasn o
change in activity during the light period. (B) Body temperature began to increase 2 h after ICV injection of visfatin and remained high until about
20 h after injection. Mean temperature after the injection time (at 0 h) was significantly different between groups. Data are represented as mean 6
SEM (n=10). ***P,0.001 vs. control rats injected with 0.9% saline solution.
doi:10.1371/journal.pone.0015981.g002
Figure 3. Visfatin-induced increases in hypothalamic mRNA
levels of pro-inflammatory cytokines and prostaglandin-syn-
thesizing enzymes. RNA was extracted from rat hypothalami 6 h after
ICV injection of visfatin. mRNA expressions encoding TNF-a, IL-1b, COX2
and mPGES-1 were determined using real-time PCR. Visfatin signifi-
cantly stimulated the expressions of TNF-a (A), IL-1b (B), COX2 (C) and
mPGES-1 (D) mRNA in the hypothalamus. Data are represented as mean
6 SEM (n=6). **P,0.01 and ***P,0.001 vs. control rats injected with
0.9% saline solution.
doi:10.1371/journal.pone.0015981.g003
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Some studies have reported higher plasma visfatin levels in obese
individuals [11,24], whereas other studies have reported opposing
findings [12,25].
The present study evaluated the effects of visfatin on food intake
and body weight to clarify the relationship between visfatin and
obesity. We found that ICV-injected visfatin decreased food intake
and body weight. Moreover, we observed that this peptide induced
a much greater decrease in body weight compared to that of a
matched, pair-fed group, suggesting that one of the main roles of
visfatin is in the processes of energy consumption. Surprisingly,
ICV-visfatin injections decreased the locomotor activities of rats.
We also found that visfatin dramatically increased body temper-
ature. Collectively, these results suggest that visfatin is involved in
a sickness response in the brain, as increased body temperature
and decreased locomotor activity are representative indicators of
an inflammatory sickness response.
We also found that pro-inflammatory cytokines (TNF-a and
IL1-b) and PGE2-synthesizing enzymes (COX2 and mPGES1)
were profoundly stimulated by visfatin. Recent studies have
suggested that visfatin may have a role in the regulation of
peripheral inflammatory responses [16,17]. Serum visfatin
concentration is also increased in patients with inflammatory
diseases like chronic kidney disease, sepsis and cancer
[19,20,21]. Additionally, visfatin activates other pro-inflamma-
tory cytokines as well, including IL-6, IL-1b and TNF-a in
human monocytes [18]. A key mediator for inflammatory
process, PGE2 plays an important role in the development of
sickness behaviors observed during inflammatory states [5]. In
the brain, PGE2 is produced by a variety of inflammatory
signals such as endotoxins or cytokines and is one of the critical
inducers of sickness responses [26]. Previous research has also
found that COX2 is involved in an inflammatory response.
Selective pharmacological or genetic blockade of COX2
effectively attenuates the sickness response to systemic inflam-
mation induced by LPS, a cell wall component of gram-negative
bacteria [5,27]. Collectively, these results strongly suggest that
visfatin may be involved in inflammatory sickness responses by
regulating the productions of hypothalamic pro-inflammatory
cytokines and prostaglandins.
Figure 4. Effect of COX inhibitor on visfatin-induced sickness behaviors. To determine the involvement of prostaglandins on visfatin-
induced sickness behaviors, rats were IP-injected with indomethacin (Indo) 30 min prior to injection with visfatin. Parameters such as body
temperature, locomotor activity and food intake were observed for one day after injection of visfatin. Indomethacin completely blocked the visfatin-
induced increase in body temperature (A) and partially attenuated the effects of visfatin on locomotor activity (B) and body weight (C). However,
indomethacin did not affect the visfatin-induced decrease in food intake (D). Data are represented as mean 6 SEM (n=6). **P,0.01 and ***P,0.001
vs. control rats injected with 0.9% saline solution;
#P,0.05 and
###P,0.001 vs. visfatin-injected rats.
doi:10.1371/journal.pone.0015981.g004
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sickness responses, we examined the effect of indomethacin, a
COX inhibitor, on sickness behaviors in response to visfatin.
Indomethacin completely abolished visfatin-induced hyperther-
mia and partially reversed visfatin-induced hypoactivity but did
n o ta f f e c tv i s f a t i n - i n d u c e da n o r exia. This result is unexpected
because COX inhibitors are known to reverse decreased food
intake induced by inflammatory conditions [27]. In this study,
we found that visfatin increased the synthesis of a-MSH, an
anorectic neuropeptide in normal and fast-induced hyperphagic
conditions. It may be that visfatin-induced anorexia is due in
part to effects of the central melanocortin pathway, which plays
an important role in the mediation of anorexia and cachexia
[10]. Indeed, we found that blocking melanocortin receptors
with SHU9119, a MC3/4R antagonist, attenuated the anorectic
effect of visfatin. Thus, the melanocortin pathway is a likely
mediator of visfatin effects on feeding behavior. Additionally, we
found that administration of SHU9119 did not block visfatin-
induced hyperthermia or hypoactivity, but that it rather exerted
an immediate additional increase in body temperature. Inter-
estingly, this immediate increased body temperature by
SHU9119 well coincides with a previous study showing that
central administration of SHU9119 exacerbated LPS-induced
fever during the period 0–8 h after injection of LPS, but not
during subsequent intervals, while it did not affect LPS-induced
hypoactivity [28]. Thus, evidence suggests that the hypothalamic
melanocortin pathway is not a critical mediator for visfatin-
induced hyperthermia and hypoactivity. Our results are also in
line with those of previous studies that have found that ICV
injection of low doses of a-MSH inhibits hyperthermia that is
induced by endotoxins or cytokines [28]. Collectively, such
results suggest that visfatin acts on food intake via the
melanocortin pathway, and it acts on hyperthermia and
hypoactivity mainly via COX.
In summary, our results indicate that visfatin is a regulator of
behavioral responses to sickness and acts as a classic inflammatory
signal to activate responses to acute inflammation. To our
knowledge, our study is one of the first to differentiate two
pathways of action for visfatin-induced anorexia, hypothermia,
and hypoactivity.
Materials and Methods
Animals
Two-month-old male Sprague-Dawley rats (Daehan Animal
Breeding Company, Chungwon, Korea) were used, and animal
experiments were conducted in accordance with the regulations of
the University of Ulsan and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. The
Institutional Review Board of University of Ulsan approved the
experimental procedures (permission number UOU-2008-07).
Rats were housed in a room with a conditioned photoperiod
(12 h light/12 h dark, lights on from 0600-1800) and a regulated
temperature (23–25uC) and were allowed ad libitum access to tap
water and rat chow pellets.
Micropunch dissection
Rats were sacrificed via decapitation, and their brains were
rapidly removed and frozen in 2-methylbutane on dry ice for
5 min. Brains were sectioned (500-mm thickness) in a cryostat at
-15uC and were mounted onto glass slides. Using anatomical
landmarks from the rat brain atlas, the ARC was identified and
Figure 5. Effect of ICV administration of visfatin on a-MSH synthesis in the ARC. To determine the effect of visfatin on a-MSH synthesis,
visfatin was ICV-injected into the lateral ventricles of rats deprived of food for one day. Ninety minutes after the injection, the rats were sacrificed and
their brains were fixed via transcardiac perfusion for IHC or were sliced for excising the ARC using a micropunch. Expressions of a-MSH (A) and POMC
(B) were determined through IHC and real-time PCR, respectively. To determine the effects of prostaglandins on visfatin-induced changes in POMC
expression, indomethacin (Indo) was IP-injected 30 min prior to injection of visfatin, and its effect was determined using real-time PCR (C). 3V=third
ventricle. Data (in B and C) are represented as mean 6 SEM (n=6). *P,0.05 and **P,0.01 vs. control rats injected with 0.9% saline solution;
###P,0.001 vs. fasting. Scale bar =50 mm.
doi:10.1371/journal.pone.0015981.g005
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(Stoelting, Wood Dale, IL). Micro-punched ARC fragments were
stored in microcentrifuge tubes at -80uC.
Real-time PCR
Total RNA was isolated from the total hypothalamus and
micro-punched ARC using Trizol reagent (Sigma-Aldrich). The
samples were reverse-transcribed and amplified using real-time
PCR with the following primer sets: POMC sense primer, 59-GCT
AGG TAA CAA ACG AAT GG-39; antisense primer, 59-GCA
TTT TCT GTG CTT TCT CT-39; TNF-a sense primer, 59-
AAA GCA TGA TCC GAG ATG TG-39; antisense primer, 59-
AGC AGG AAT GAG AAG AGG CT-39; IL-1b sense primer,
59- CAT CTT TGA AGA AGA GCC CG-39; antisense primer,
59- GGG ATT TTG TCG TTG CTT GT-39; COX2 sense
primer, 59-ACC AGA GCA GAG AGA TGA AA-39; antisense
primer, 59-GAG AGA CTG AAT TGA GGC AG-39; mPGES1
sense primer, 59-CTG CTG GTC ATC AAG ATG TAC G-39;
antisense primer, 59-CCC AGG TAG GCC ACG GTG TGT-39;
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense prim-
er, 59-TGT GAA CGG ATT TGG CCG TA-39; and antisense
primer, 59-ACT TGC CGT GGG TAG AGT CA-39. Real-time
PCR was carried out in capillaries of the DNA Engine Opticon
Continuous Fluorescence Detection System (MJ Research Inc.,
Waltham, MA) for approximately 40 cycles as follows: at 94uC for
30 sec, 56uC for 30 sec and 72uC for 35 sec.
Immunohistochemistry (IHC)
Rats were anesthetized with tribromoethanol (250 mg/kg B.W.,
Sigma-Aldrich) and transcardially perfused with 100 ml ice-cold
0.1M phosphate buffer (PB, pH 7.4), followed by 100 ml 4%
paraformaldehyde. Brains were dissected and post-fixed overnight
in the same fixative containing 30% sucrose. Slide-mounted
sections were prepared with a cryostat. We followed the IHC
protocol described previously [29], using a primary antibody for a-
MSH (1:10000; Millipore, Billerica, MA), and secondary antibody
for sheep IgG (1:500; Vector, Burlingame, CA). Immunoreactive
signals were visualized using the Tyramide Signal Amplification
System (NEN Life Science, Boston, MA), and images were
obtained using fluorescence microscopy.
Figure 6. Effects of melanocortin receptors 3/4 antagonist on visfatin-induced sickness behaviors. Two-month-old male rats were ICV-
injected with visfatin or vehicle 30 min after ICV injection of SHU9119 and were allowed access to food immediately after the final treatment. (A)
Change in food intake was measured 24 h after the injections of SHU9119 and visfatin. (B, C) Changes in locomotor activity (B) and body temperature
(C) were monitored in rats IP-implanted with telemetry-transmitters. In C, time 0 indicates visfatin injection. Data are represented as mean 6 SEM
(n=6). **P,0.01 and ***P,0.001 vs. control rats injected with 0.9% saline solution;
##P,0.01 vs. visfatin-injected rats.
doi:10.1371/journal.pone.0015981.g006
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Rats were anesthetized via an IP injection of tribromoethanol
(250 mg/kg B.W., Sigma-Aldrich) and were placed in a stereotaxic
apparatus (Stoelting, Wood Dale, IL). A polyethylene cannula (o.d.
1.05 mm, i.d. 0.35 mm) was implanted into the lateral ventricle
(coordinates: AP=1.0 mm caudal to the bregma; V=3.6 mm
from the dura mater; L=0.16 mm from the mid-line) and secured
to the skull with dental cement. The rats were immediately sutured
and placed in individual cages. After one week of recovery, test
materials were injected through the cannula.
ICV administration of visfatin
To determine whether visfatin regulates sickness responses in
the brain, rats were ICV-injected with recombinant rat visfatin
(2 mg, Adipogene, Seoul, Korea). Rats were sacrificed 90 min or
6 h after visfatin injection. The hypothalamus was dissected and
the RNA was isolated.
Treatment of COX inhibitor and MC3/4R antagonist
To determine whether MC3/4R and COX pathways mediate
sickness behaviors induced by the ICV administration of visfatin,
we pre-injected SHU9119 (an MC3/4R antagonist; Phoenix
Pharmaceuticals, Burlingame, CA) and indomethacin (a COX
inhibitor; Sigma-Aldrich) 30 min prior to visfatin injection.
Immediately after injection, rats were allowed ad libitum access to
food, and their cumulative food intake was measured 24 h after
the injection. To test the effects of SHU9119 and indomethacin on
visfatin-induced hyperthermia and hypoactivity, body temperature
and locomotor activity were measured using telemetry transmitters
implanted into the rats following the procedures described above.
Measurement of body temperature and locomotor
activity
Abdominal temperature and locomotor activity were measured
in male Sprague-Dawley rats using biotelemetry transmitters
(Mini-Mitter, Bend, OR) implanted into the abdominal cavity one
week prior to the experiment. Prior to surgery, rats were
anesthetized with tribromoethanol (250 mg/kg B.W., Sigma-
Aldrich). The output (frequency in Hz) was monitored by a
receiver (model RA 1000; Mini-Mitter) placed under each cage. A
data acquisition system (Vital View; Mini-Mitter) was used for
automatic control of data collection and analysis. Body temper-
ature was recorded at 10-min intervals. Changes in locomotor
activity were detected as changes in the position of the implanted
transmitter over the receiver board, which resulted in a change in
the signal strength and was recorded as a pulse of activity. Activity
pulses were counted every 10 min and were summed after 12 h as
a cumulative measure of daytime or nighttime activity. Locomotor
activity scores are expressed as activity counts per 12 h.
Statistics
All results are expressed as mean 6 standard error of measure
(SEM; n is given in the figure legends). For cumulative food intake,
statistical analyses were performed using repeated measures
ANOVA with Bonferroni post-hoc analyses. Student’s t-test was
used for comparison of two groups.
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